Bioventix PLC (DE:51B)

FRANKFURT:51B

51B

Bioventix

RESEARCH TOOLSreports

Bioventix (51B) Price & Analysis

0 Followers

51B Stock Chart & Stats

€19.70

-€0.20(-0.51%)

At close: Jan 08 4:00 PM EST

€19.70

-€0.20(-0.51%)

Day’s Range― - ―

52-Week Range€14.90 - €33.00

Previous CloseN/A

Volume0.00

Average Volume (3M)2.00

Market Cap

€93.88M

Enterprise Value€82.21M

Total Cash (Recent Filing)€5.30M

Total Debt (Recent Filing)€0.00

Price to Earnings (P/E)10.9

Beta0.48

Next Earnings

Oct 26, 2026

EPS Estimate

0.76

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)1.42

Shares Outstanding5,224,860

10 Day Avg. Volume0

30 Day Avg. Volume2

Financial Highlights & Ratios

PEG Ratio-2.93

Price to Book (P/B)12.43

Price to Sales (P/S)10.95

P/FCF Ratio20.47

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)0.02

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Conservative Balance SheetZero reported debt and a conservative balance sheet provide durable financial resilience, lowering solvency risk and preserving flexibility to fund operations, dividends or opportunistic investments from internal resources. High returns on equity reinforce efficient capital use.

Strong Cash ConversionNear-1.0 free cash flow conversion indicates earnings reliably convert to cash, supporting sustained dividends, R&D or capital-light growth without relying on external financing. This quality cash generation underpins long-term financial stability and shareholder returns.

Elite Profitability And MarginsVery high gross and net margins reflect a differentiated, high-value product set and pricing power in the diagnostic reagent niche. Such margin durability supports strong free cash flow and resilience to cyclical revenue swings over a multi-month horizon.

Bears Say

Slowing Revenue And FCF MomentumA recent decline in revenue and free cash flow signals weakening operating momentum that, if persistent, can reduce scale benefits, compress absolute profits and limit reinvestment capacity. Sustained top-line weakness could pressure long-term royalty streams and growth.

Exposure To Market Challenges (China)Reported pressure in China and other market headwinds indicate geographic or customer-concentration risks that can persist for months. Given Bioventix's B2B diagnostic exposures, sustained weakness in key markets could materially reduce recurring reagent sales and royalties.

Small Operational Scale / Concentration RiskA very small workforce implies operational concentration and dependence on a few key individuals, increasing execution and continuity risk. Limited internal capacity can constrain simultaneous commercialisation, customer support and new product development over the medium term.

Bioventix News

Bioventix CFO Increases Stake Through Dividend Reinvestment Plan

Bioventix ( ($GB:BVXP) ) just unveiled an announcement. Bioventix has disclosed a director dealing after Chief Financial Officer...

2M ago

Bioventix Ties Executive Share Options to Neurological Test Revenue Milestone

Bioventix ( ($GB:BVXP) ) just unveiled an update. Bioventix plc has granted share options to chief executive Peter...

2M ago

Bioventix Chairman Increases Stake with Share Purchase

Bioventix ( ($GB:BVXP) ) just unveiled an update. Bioventix has announced that its non-executive chairman, Ian Nicholson, has...

2M ago

Bioventix CEO Increases Stake After Share Purchases with Spouse

Bioventix ( ($GB:BVXP) ) has issued an announcement. Bioventix has disclosed that chief executive Peter Harrison and his...

2M ago

Bioventix CFO Increases Personal Stake with Share Purchase

Bioventix ( ($GB:BVXP) ) has shared an update. Bioventix plc reported that its Chief Financial Officer, Bruce Hiscock,...

2M ago

Bioventix Leans on Neuro Antibodies as Interim Profits Hold Steady

Bioventix ( ($GB:BVXP) ) just unveiled an announcement. Bioventix reported a modest dip in interim revenue to £6.16m...

3M ago

Bioventix strengthens board with appointment of diagnostics veteran Chris Yates

The latest update is out from Bioventix ( ($GB:BVXP) ). Bioventix plc, the AIM-listed UK antibody developer and...

4M ago

Bioventix CFO Increases Stake with Share Purchase

Bioventix ( ($GB:BVXP) ) has shared an update. Bioventix plc announced that its Chief Financial Officer, Bruce Hiscock,...

7M ago

Bioventix Posts Annual Report and Announces AGM

The latest announcement is out from Bioventix ( ($GB:BVXP) ). Bioventix plc has announced the posting of its...

7M ago

Bioventix CEO Increases Stake in Company

The latest update is out from Bioventix ( ($GB:BVXP) ). Bioventix plc announced that its CEO, Peter Harrison,...

7M ago

51B FAQ

What was Bioventix PLC’s price range in the past 12 months?

Bioventix PLC lowest stock price was €14.90 and its highest was €33.00 in the past 12 months.

What is Bioventix PLC’s market cap?

Bioventix PLC’s market cap is €93.88M.

When is Bioventix PLC’s upcoming earnings report date?

Bioventix PLC’s upcoming earnings report date is Oct 26, 2026 which is in 135 days.

How were Bioventix PLC’s earnings last quarter?

Bioventix PLC released its earnings results on Mar 30, 2026. The company reported €0.792 earnings per share for the quarter, beating the consensus estimate of €0.596 by €0.196.

Is Bioventix PLC overvalued?

According to Wall Street analysts Bioventix PLC’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Bioventix PLC pay dividends?

Bioventix PLC does not currently pay dividends.

What is Bioventix PLC’s EPS estimate?

Bioventix PLC’s EPS estimate is 0.76.

How many shares outstanding does Bioventix PLC have?

Bioventix PLC has 5,224,860 shares outstanding.

What happened to Bioventix PLC’s price movement after its last earnings report?

Bioventix PLC reported an EPS of €0.792 in its last earnings report, beating expectations of €0.596. Following the earnings report the stock price went up 5.96%.

Which hedge fund is a major shareholder of Bioventix PLC?

Currently, no hedge funds are holding shares in DE:51B

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Bioventix Stock Smart Score

Neutral

Fundamentals

Return on Equity

65.83%

Trailing 12-Months

Asset Growth

0.19%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Bioventix PLC

Bioventix PLC focuses on the development, manufacturing, and global provision of sheep monoclonal antibodies (SMAs) for various diagnostic purposes. The company's extensive product line features purified SMAs that facilitate testing for critical areas such as thyroid conditions, vitamin D deficiencies, cardiac health markers, detection of drugs of abuse, fertility assessments, infectious diseases, oncology, and other diverse medical indications. Additionally, Bioventix PLC offers tailored contract SMA development and specialized recombinant services. The London, UK-based firm was established in 2003.